198 related articles for article (PubMed ID: 15001973)
1. CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects.
Giessmann T; Modess C; Hecker U; Zschiesche M; Dazert P; Kunert-Keil C; Warzok R; Engel G; Weitschies W; Cascorbi I; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2004 Mar; 75(3):213-22. PubMed ID: 15001973
[TBL] [Abstract][Full Text] [Related]
2. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans.
Oswald S; Haenisch S; Fricke C; Sudhop T; Remmler C; Giessmann T; Jedlitschky G; Adam U; Dazert E; Warzok R; Wacke W; Cascorbi I; Kroemer HK; Weitschies W; von Bergmann K; Siegmund W
Clin Pharmacol Ther; 2006 Mar; 79(3):206-17. PubMed ID: 16513445
[TBL] [Abstract][Full Text] [Related]
3. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans.
Giessmann T; May K; Modess C; Wegner D; Hecker U; Zschiesche M; Dazert P; Grube M; Schroeder E; Warzok R; Cascorbi I; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2004 Sep; 76(3):192-200. PubMed ID: 15371980
[TBL] [Abstract][Full Text] [Related]
4. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
[TBL] [Abstract][Full Text] [Related]
5. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
Bernsdorf A; Giessmann T; Modess C; Wegner D; Igelbrink S; Hecker U; Haenisch S; Cascorbi I; Terhaag B; Siegmund W
Br J Clin Pharmacol; 2006 Apr; 61(4):440-50. PubMed ID: 16542205
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.
Saito M; Kawana J; Ohno T; Hanada K; Kaneko M; Mihara K; Shiomi M; Nagayama M; Sumiyoshi T; Ogata H
Biol Pharm Bull; 2010; 33(8):1378-84. PubMed ID: 20686235
[TBL] [Abstract][Full Text] [Related]
7. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins.
Oswald S; Giessmann T; Luetjohann D; Wegner D; Rosskopf D; Weitschies W; Siegmund W
Clin Pharmacol Ther; 2006 Nov; 80(5):477-85. PubMed ID: 17112804
[TBL] [Abstract][Full Text] [Related]
8. Variation in the CYP2D6 genotype is not associated with carvedilol dose changes in patients with heart failure.
Shihmanter R; Nulman I; Goland S; Caspi A; Bar-Haim A; Harary I; Berkovitch M; Arcavi L
J Clin Pharm Ther; 2014 Aug; 39(4):432-8. PubMed ID: 24673480
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers.
Honda M; Nozawa T; Igarashi N; Inoue H; Arakawa R; Ogura Y; Okabe H; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2005 Aug; 28(8):1476-9. PubMed ID: 16079496
[TBL] [Abstract][Full Text] [Related]
10. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
12. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
13. Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism.
Nardotto GHB; Coelho EB; Paiva CE; Lanchote VL
J Clin Pharmacol; 2017 Jun; 57(6):760-769. PubMed ID: 28114735
[TBL] [Abstract][Full Text] [Related]
14. Effects of myricetin on the bioavailability of carvedilol in rats.
Lee W; Woo ER; Choi JS
Pharm Biol; 2012 Apr; 50(4):516-22. PubMed ID: 22132944
[TBL] [Abstract][Full Text] [Related]
15. Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Dilger K; Greiner B; Fromm MF; Hofmann U; Kroemer HK; Eichelbaum M
Pharmacogenetics; 1999 Oct; 9(5):551-9. PubMed ID: 10591535
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
[TBL] [Abstract][Full Text] [Related]
17. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.
Haenisch S; May K; Wegner D; Caliebe A; Cascorbi I; Siegmund W
Pharmacogenet Genomics; 2008 Apr; 18(4):357-65. PubMed ID: 18334920
[TBL] [Abstract][Full Text] [Related]
18. Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.
Naesens M; Kuypers DR; Streit F; Armstrong VW; Oellerich M; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2006 Nov; 80(5):509-21. PubMed ID: 17112807
[TBL] [Abstract][Full Text] [Related]
19. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response.
Materna V; Pleger J; Hoffmann U; Lage H
Gynecol Oncol; 2004 Jul; 94(1):152-60. PubMed ID: 15262134
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective disposition of carvedilol is determined by CYP2D6.
Zhou HH; Wood AJ
Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]